OASMY Stock - Vivesto AB
Unlock GoAI Insights for OASMY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $6.61M | $1.01M | $26.19M | $201.84M |
| Gross Profit | N/A | $6.61M | $-10,656,000 | $-17,930,000 | $215.84M |
| Gross Margin | N/A | 100.0% | -1049.9% | -68.5% | 106.9% |
| Operating Income | $-41,962,000 | $-132,170,999 | $-356,719,000 | $-128,647,000 | $-30,086,000 |
| Net Income | $-39,754,000 | $-128,740,000 | $-367,030,000 | $-138,945,000 | $-10,533,000 |
| Net Margin | N/A | -1947.1% | -36160.6% | -530.5% | -5.2% |
| EPS | $N/A | $N/A | $-2.22 | $-0.93 | $-0.07 |
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
Visit WebsiteEarnings History & Surprises
OASMYEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 18, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | — | — | — | — |
Q3 2025 | Aug 20, 2025 | — | — | — | — |
Q2 2025 | May 8, 2025 | — | $-0.02 | — | — |
Q1 2025 | Feb 20, 2025 | — | $-0.02 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-0.02 | — | — |
Q3 2024 | Aug 22, 2024 | — | $-0.01 | — | — |
Q2 2024 | May 23, 2024 | — | $-0.01 | — | — |
Q1 2024 | Feb 22, 2024 | — | $-0.12 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.02 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.16 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.11 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-1.29 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.42 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.23 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.16 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.02 | — | — |
Q4 2021 | Nov 18, 2021 | — | $-0.21 | — | — |
Q3 2021 | Aug 19, 2021 | — | $-0.35 | — | — |
Latest News
Frequently Asked Questions about OASMY
What is OASMY's current stock price?
What is the analyst price target for OASMY?
What sector is Vivesto AB in?
What is OASMY's market cap?
Does OASMY pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to OASMY for comparison